Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases

Jennifer M. Atkinson, Robert A. Falconer, Dylan R. Edwards, Caroline J. Pennington, Catherine S. Siller, Steven D. Shnyder, Michael C. Bibby, Laurence H. Patterson, Paul M. Loadman, Jason H. Gill

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Vascular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomitant with tumor shrinkage. Several VDAs have progressed into early clinical trials, but their therapeutic value seems to be compromised by systemic toxicity. In this report, we describe the design and characterization of a novel VDA, ICT2588, that is nontoxic until activated specifically in the tumor by membrane-type 1 matrix metalloproteinase (MT1-MMP). HT1080 cancer cells expressing MT1-MMP were selectively chemosensitive to ICT2588, whereas MCF7 cells that did not express MT1-MMP were nonresponsive. Preferential hydrolysis of ICT2588 to its active metabolite (ICT2552) was observed in tumor homogenates of HT1080 relative to MCF7 homogenates, mouse plasma, and liver homogenate. ICT2588 activation was inhibited by the MMP inhibitor ilomastat. In HT1080 tumor-bearing mice, ICT2588 administration resulted in the formation of the active metabolite, diminution of tumor vasculature, and hemorrhagic necrosis of the tumor. The antitumor activity of ICT2588 was superior to its active metabolite, exhibiting reduced toxicity, improved therapeutic index, enhanced pharmacodynamic effect, and greater efficacy. Coadministration of ICT2588 with doxorubicin resulted in a significant antitumor response (22.6 d growth delay), which was superior to the administration of ICT2588 or doxorubicin as a single agent, including complete tumor regressions. Our findings support the clinical development of ICT2588, which achieves selective VDA targeting based on MT-MMP activation in the tumor microenvironment.

Original languageEnglish (US)
Pages (from-to)6902-6912
Number of pages11
JournalCancer Research
Volume70
Issue number17
DOIs
StatePublished - Sep 1 2010

Fingerprint

Membrane-Associated Matrix Metalloproteinases
Blood Vessels
Matrix Metalloproteinase 14
Neoplasms
Doxorubicin
ICT2588
Tumor Microenvironment
Matrix Metalloproteinase Inhibitors
MCF-7 Cells
Matrix Metalloproteinases
Hydrolysis
Necrosis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Atkinson, J. M., Falconer, R. A., Edwards, D. R., Pennington, C. J., Siller, C. S., Shnyder, S. D., ... Gill, J. H. (2010). Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Research, 70(17), 6902-6912. https://doi.org/10.1158/0008-5472.CAN-10-1440
Atkinson, Jennifer M. ; Falconer, Robert A. ; Edwards, Dylan R. ; Pennington, Caroline J. ; Siller, Catherine S. ; Shnyder, Steven D. ; Bibby, Michael C. ; Patterson, Laurence H. ; Loadman, Paul M. ; Gill, Jason H. / Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. In: Cancer Research. 2010 ; Vol. 70, No. 17. pp. 6902-6912.
@article{79b6848877a74f8e9f3752142444044c,
title = "Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases",
abstract = "Vascular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomitant with tumor shrinkage. Several VDAs have progressed into early clinical trials, but their therapeutic value seems to be compromised by systemic toxicity. In this report, we describe the design and characterization of a novel VDA, ICT2588, that is nontoxic until activated specifically in the tumor by membrane-type 1 matrix metalloproteinase (MT1-MMP). HT1080 cancer cells expressing MT1-MMP were selectively chemosensitive to ICT2588, whereas MCF7 cells that did not express MT1-MMP were nonresponsive. Preferential hydrolysis of ICT2588 to its active metabolite (ICT2552) was observed in tumor homogenates of HT1080 relative to MCF7 homogenates, mouse plasma, and liver homogenate. ICT2588 activation was inhibited by the MMP inhibitor ilomastat. In HT1080 tumor-bearing mice, ICT2588 administration resulted in the formation of the active metabolite, diminution of tumor vasculature, and hemorrhagic necrosis of the tumor. The antitumor activity of ICT2588 was superior to its active metabolite, exhibiting reduced toxicity, improved therapeutic index, enhanced pharmacodynamic effect, and greater efficacy. Coadministration of ICT2588 with doxorubicin resulted in a significant antitumor response (22.6 d growth delay), which was superior to the administration of ICT2588 or doxorubicin as a single agent, including complete tumor regressions. Our findings support the clinical development of ICT2588, which achieves selective VDA targeting based on MT-MMP activation in the tumor microenvironment.",
author = "Atkinson, {Jennifer M.} and Falconer, {Robert A.} and Edwards, {Dylan R.} and Pennington, {Caroline J.} and Siller, {Catherine S.} and Shnyder, {Steven D.} and Bibby, {Michael C.} and Patterson, {Laurence H.} and Loadman, {Paul M.} and Gill, {Jason H.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-10-1440",
language = "English (US)",
volume = "70",
pages = "6902--6912",
journal = "Cancer Research",
issn = "0008-5472",
number = "17",

}

Atkinson, JM, Falconer, RA, Edwards, DR, Pennington, CJ, Siller, CS, Shnyder, SD, Bibby, MC, Patterson, LH, Loadman, PM & Gill, JH 2010, 'Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases', Cancer Research, vol. 70, no. 17, pp. 6902-6912. https://doi.org/10.1158/0008-5472.CAN-10-1440

Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. / Atkinson, Jennifer M.; Falconer, Robert A.; Edwards, Dylan R.; Pennington, Caroline J.; Siller, Catherine S.; Shnyder, Steven D.; Bibby, Michael C.; Patterson, Laurence H.; Loadman, Paul M.; Gill, Jason H.

In: Cancer Research, Vol. 70, No. 17, 01.09.2010, p. 6902-6912.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases

AU - Atkinson, Jennifer M.

AU - Falconer, Robert A.

AU - Edwards, Dylan R.

AU - Pennington, Caroline J.

AU - Siller, Catherine S.

AU - Shnyder, Steven D.

AU - Bibby, Michael C.

AU - Patterson, Laurence H.

AU - Loadman, Paul M.

AU - Gill, Jason H.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Vascular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomitant with tumor shrinkage. Several VDAs have progressed into early clinical trials, but their therapeutic value seems to be compromised by systemic toxicity. In this report, we describe the design and characterization of a novel VDA, ICT2588, that is nontoxic until activated specifically in the tumor by membrane-type 1 matrix metalloproteinase (MT1-MMP). HT1080 cancer cells expressing MT1-MMP were selectively chemosensitive to ICT2588, whereas MCF7 cells that did not express MT1-MMP were nonresponsive. Preferential hydrolysis of ICT2588 to its active metabolite (ICT2552) was observed in tumor homogenates of HT1080 relative to MCF7 homogenates, mouse plasma, and liver homogenate. ICT2588 activation was inhibited by the MMP inhibitor ilomastat. In HT1080 tumor-bearing mice, ICT2588 administration resulted in the formation of the active metabolite, diminution of tumor vasculature, and hemorrhagic necrosis of the tumor. The antitumor activity of ICT2588 was superior to its active metabolite, exhibiting reduced toxicity, improved therapeutic index, enhanced pharmacodynamic effect, and greater efficacy. Coadministration of ICT2588 with doxorubicin resulted in a significant antitumor response (22.6 d growth delay), which was superior to the administration of ICT2588 or doxorubicin as a single agent, including complete tumor regressions. Our findings support the clinical development of ICT2588, which achieves selective VDA targeting based on MT-MMP activation in the tumor microenvironment.

AB - Vascular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomitant with tumor shrinkage. Several VDAs have progressed into early clinical trials, but their therapeutic value seems to be compromised by systemic toxicity. In this report, we describe the design and characterization of a novel VDA, ICT2588, that is nontoxic until activated specifically in the tumor by membrane-type 1 matrix metalloproteinase (MT1-MMP). HT1080 cancer cells expressing MT1-MMP were selectively chemosensitive to ICT2588, whereas MCF7 cells that did not express MT1-MMP were nonresponsive. Preferential hydrolysis of ICT2588 to its active metabolite (ICT2552) was observed in tumor homogenates of HT1080 relative to MCF7 homogenates, mouse plasma, and liver homogenate. ICT2588 activation was inhibited by the MMP inhibitor ilomastat. In HT1080 tumor-bearing mice, ICT2588 administration resulted in the formation of the active metabolite, diminution of tumor vasculature, and hemorrhagic necrosis of the tumor. The antitumor activity of ICT2588 was superior to its active metabolite, exhibiting reduced toxicity, improved therapeutic index, enhanced pharmacodynamic effect, and greater efficacy. Coadministration of ICT2588 with doxorubicin resulted in a significant antitumor response (22.6 d growth delay), which was superior to the administration of ICT2588 or doxorubicin as a single agent, including complete tumor regressions. Our findings support the clinical development of ICT2588, which achieves selective VDA targeting based on MT-MMP activation in the tumor microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=77956279673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956279673&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-1440

DO - 10.1158/0008-5472.CAN-10-1440

M3 - Article

C2 - 20663911

AN - SCOPUS:77956279673

VL - 70

SP - 6902

EP - 6912

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 17

ER -